ABSTRACT The outcome of drug induced pleurodesis has been evaluated in a non-randomised retrospective study of 67 patients with recurrent malignant pleural effusions treated during 1976-83. Fourteen died within 30 days of treatment. Of the remaining 53 patients, 26 studied during 1976-80 were treated with intrapleural mustine hydrochloride, while 27 studied during 1978-83 were treated with intrapleural Corynebacterium parvum. There was no significant difference between the groups in age, sex, or tumour type, most tumours being secondary to bronchial neoplasms. Corynebacterium parvum successfully prevented reaccumulation of the effusion in 24 (92%) patients, while mustine was effective in only 17 (65%) (p < 0.05). Data on survival were obtained on 47 cases where a single agent was used to induce pleurodesis. In 25 patients treated with Cparvum the mean survival was 251 (range 31-1143) days, compared with 119 (range 31-380) days for the 22 patients in whom mustine was used. Survival of the Cparvum group was significantly greater (p < 0.01). The difference was principally due to the greater number of long term survivors in the C parvum group, nine of this group living for more than 180 days (mean 574, range 180-1143 days) compared with only four such survivors in the mustine group (mean 263, range 193-380 days). This study confirms our initial impression that C parvum is highly effective in controlling recurrent malignant pleural effusions. The finding of unexpected long term survivors with C parvum treatment suggests that this treatment may have an additional effect on the progression of disease, a finding that merits further investigation.
Pleural effusion is a common complication of advanced cancer'; it is often symptomatic and carries a poor prognosis.2 Pleural aspiration is normally undertaken to relieve symptoms and this is often followed by the instillation of an agent to promote pleurodesis and prevent reaccumulation. Several different methods and agents3-7 have been advocated. In 1980 we reported a randomised study of intrapleural Corynebacterium parvum compared with the previous standard treatment of intrapleural mustine hydrochloride in patients with recurrent malignant pleural effusions presenting to a respiratory unit.8 As C parvum was effective and relatively free from side effects we now routinely use this agent in such patients. It became apparent that some patients had an unexpectedly long survival after C parvum treatment. We have therefore reviewed our recent experience with C parvum in malignant pleural effusion and compared the survival of these patients with that of similar patients treated with mustine. (table) , although in six patients receiving mustine the effusion was diagnosed as malignant on the basis of endoscopic appearances and clinical course rather than cytological examination. The size of the effusion, aspiration volume, and interaspiration intervals was similar in the two study groups. In the C parvum group 70% had primary pulmonary tumours, compared with 65% in the mustine group, the remainder comprising metastatic deposits from renal, bladder, ovarian, stomach, colon, and breast carcinoma. C parvum produced 23 complete successes, one partial success, and two failures. In one patient a collapsed lung resulted from total bronchial occlusion with tumour. The overall success rate with C parvum was thus 92%. In the 26 patients treated with mustine, there were 13 complete successes, four partial successes, Tumour cell types in all patients surviving more than 30 days (column A) and in those surviving more than 180 days after treatment with Corynebacterium parvum or mustine tOne patient is still living (after 3.5 years).
Methods
Further experience of Corynebacterium parvum in malignant pleural effusion and nine failures. With an overall success rate of 65% mustine was significantly less successful than C parvum (p < 0.05). Success with either sclerosing treatment was not obviously related to tumour cell type. All patients treated with mustine were nauseated and most vomited, in addition to experiencing local chest pain. Intrapleural C parvum gave rise to fever (38°C), which undulated for two to three days, in seven (32%) patients. A similar number experienced chest pain, which was readily controlled with simple analgesics and did not last for more than 24 hours. Nausea was experienced by only a few and no patients vomited.
The mean survival in the 25 patients treated solely with C parvum was 251 (median 120) days compared with 119 (median 120) days in the 22 patients treated with mustine alone. This difference was largely due to the greater number of long term survivors in the C parvum group, nine patients living for more than 180 days (mean survival 574, median 448, range 180-1143 days) compared with only four mustine treated patients (mean survival 263, median 240, range 193-380 days). Overall survival was significantly longer in the C parvum group (p < 0.01). In contrast, in patients living for less than 180 days, there was Little difference in survival between the two groups (fig). Among patients included in the original randomised study comparing C parvum with mustine treatment,8 survival was again significantly prolonged (p < 0.01) in those treated with C parvum. The mean survival with C parvum was 246 days (median 147, range 64-1143 days) and three patients survived longer than 180 days. With mustine the mean survival was 97 days, (median 120, range 31-150 days).
The two groups were comparable in respect of treatment offered in addition to pleurodesis; five C.parvum treated ----Mustine treated patients in the C parvum group and four in the mustine group received radiotherapy and two in each group received supplementary cyclophosphamide.
Of the nine patients surviving more than 180 days who were treated with C parvum, three received radiotherapy but in only one case might this have prolonged survival. This patient had squamous cell carcinoma while the other two were probably unaffected, their tumours being adenocarcinomas of the bronchus. The remaining six patients received no additional treatment.
Discussion
This study of a larger number of patients confirms our initial findings8 that C parvum is a significantly more effective pleurodesing agent than mustine hydrochloride and is better tolerated. In this retrospective analysis the two agents were in the main administered at different times, most patients treated before 1980 receiving 20 mg mustine while after 1980 most received C parvum 7 mg. Other aspects which might have affected the results were, however, unaltered; there was a standard technique for instillation of the agents and standard care and supervision of patients. Furthermore, we could find no evidence of any change in referral pattern of patients with pleural effusion in this period; this is supported by the similarity in age distribution and pathological type in the two studies, the improvement in histopathological diagnosis in the latter group reflecting a general improvement in diagnostic techniques over this period. The mustine treated group contained more patients without definite pleural lesions (6/33) and some of these might have lacked true pleural invasion by tumour. Such patients have, however, a poor prognosis and at thoracotomy would be expected to have evidence of Survival data for 47 patients with recurrent malignant pleural effusion, 25 treated with intrapleural Corynebacterium parvum and 22 treated with intrapleural mustine. The high rate of pleurodesis successful usually at the first attempt in patients treated with C parvum was achieved without the need for a pleural drain, with its attendant pain and morbidity; the outcome is similar to the best results reported in comparable patients treated with drains and other agents.3-' Two other series have achieved similar good results with C parvum, with successful pleurodesis in 79% and 90% of patients.'01' The results of mustine instillation were also similar to those in previous reports, showing, by contrast, about 60% efficacy'2 and a relatively high morbidity rate.
C parvum excites such a vigorous inflammatory reaction in the pleural space that bizarre chest radiographic appearances may devlop over a period of months and be mistaken for tumour extension or fluid reaccumulation. At necropsy an uneven, grossly thickened cortex of fibrous tissue is seen over the lung surface. No symptoms occurred despite these appearances.
Although detailed information about survival in malignant pleural effusions is available, it is difficult to compare groups where there are large differences in tumour types and the numbers studied are small. Most series agree that survival is short, mean survival being 3.1 (SD 0.5) months in one large series.2 This is similar to that seen in our mustine treated patients, whose mean survival was 119 (median 120, range 31-380) days. In contrast, patients treated with C parvum lived for a mean of 251 (median 120, range 31-1143) days. Survival in this group was significantly greater at the 1% level. These figures, however, disguise the true pattern of attrition seen in the figure. Over the first six months after C parvum treatment there was no significant difference in survival, but subsequently C parvum treated patients survived for much longer periods. The differences in the cell types of our study groups, with a preponderance of squamous carcinoma in the C parvum group, may be more apparent than real. Ten of the mustine treated patients were reported as having unclassified malignant cells," reflecting the tendency in the mid 1970s to report cytological findings without further subclassification. Given the usual distribution of cell types among these "unclassified" patients, at least five would be expected to be squamous carcinoma and our groups would be more comparable. A 
